Envista Holdings Co. (NYSE:NVST) Receives $20.65 Average Target Price from Brokerages

Shares of Envista Holdings Co. (NYSE:NVST) have been assigned a consensus recommendation of “Hold” from the sixteen brokerages that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $20.65.

Several research analysts recently weighed in on the stock. Leerink Partners upgraded shares of Envista from an “underperform” rating to a “market perform” rating and boosted their price target for the stock from $16.00 to $23.00 in a report on Thursday, October 31st. Needham & Company LLC restated a “hold” rating on shares of Envista in a research note on Thursday, October 31st. Piper Sandler increased their price target on Envista from $16.00 to $17.00 and gave the company a “neutral” rating in a research report on Thursday, October 31st. Mizuho began coverage on Envista in a research report on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 price objective on the stock. Finally, Robert W. Baird raised their target price on Envista from $17.00 to $22.00 and gave the company a “neutral” rating in a research report on Thursday, October 31st.

Envista Stock Up 0.9 %

NVST stock opened at $19.29 on Monday. The firm has a market capitalization of $3.32 billion, a PE ratio of -2.48, a P/E/G ratio of 2.71 and a beta of 1.31. The company has a quick ratio of 1.77, a current ratio of 2.08 and a debt-to-equity ratio of 0.42. Envista has a twelve month low of $15.15 and a twelve month high of $25.64. The stock’s 50 day moving average is $20.25 and its 200-day moving average is $18.48.

Envista (NYSE:NVST) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.03. Envista had a positive return on equity of 3.76% and a negative net margin of 53.42%. The business had revenue of $601.00 million for the quarter, compared to analysts’ expectations of $590.34 million. During the same period last year, the business earned $0.43 EPS. The business’s revenue was down 4.8% on a year-over-year basis. Sell-side analysts expect that Envista will post 0.72 EPS for the current fiscal year.

Institutional Trading of Envista

A number of institutional investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Envista during the 3rd quarter worth about $31,000. GAMMA Investing LLC increased its position in shares of Envista by 69.8% during the third quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock valued at $35,000 after buying an additional 726 shares during the period. Huntington National Bank lifted its holdings in shares of Envista by 97.8% in the third quarter. Huntington National Bank now owns 1,919 shares of the company’s stock worth $38,000 after buying an additional 949 shares in the last quarter. Blue Trust Inc. boosted its position in shares of Envista by 69.7% in the third quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock valued at $39,000 after acquiring an additional 804 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its stake in Envista by 50.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock valued at $43,000 after acquiring an additional 728 shares in the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.